Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Comparison of short- and long-term humoral immune responses to pneumococcal polysaccharide and glycoconjugate vaccines in an HIV-infected population.

Faustini SE. et al, (2024), J Infect, 89

Clinical and regulatory development strategies for Shigella vaccines intended for children younger than 5 years in low-income and middle-income countries.

Giersing BK. et al, (2023), Lancet Glob Health, 11, e1819 - e1826

Induction of Broad Immunity against Invasive Salmonella Disease by a Quadrivalent Combination Salmonella MAPS Vaccine Targeting Salmonella Enterica Serovars Typhimurium, Enteritidis, Typhi, and Paratyphi A.

Boerth EM. et al, (2023), Vaccines (Basel), 11

Efficient Autotransporter-Mediated Extracellular Secretion of a Heterologous Recombinant Protein by Escherichia coli.

Beriotto I. et al, (2023), Microbiol Spectr, 11

Salmonella Combination Vaccines: Moving Beyond Typhoid.

MacLennan CA. et al, (2023), Open Forum Infect Dis, 10, S58 - S66

Severe anaemia, iron deficiency, and susceptibility to invasive bacterial infections

Abuga KM. et al, (2023), Wellcome Open Research, 8, 48 - 48

Consequences of Shigella infection in young children: a systematic review.

Libby TE. et al, (2023), Int J Infect Dis

Complementary measurement of nontyphoidal Salmonella-specific IgG and IgA antibodies in oral fluid and serum.

Elias SC. et al, (2023), Heliyon, 9

Exploring the variables influencing the immune response of traditional and innovative glycoconjugate vaccines.

Micoli F. et al, (2023), Front Mol Biosci, 10

Immune responses to Neisseria gonorrhoeae and implications for vaccine development.

Belcher T. et al, (2023), Front Immunol, 14

Vi polysaccharide and conjugated vaccines afford similar early, IgM or IgG-independent control of infection but boosting with conjugated Vi vaccines sustains the efficacy of immune responses.

Jossi SE. et al, (2023), Front Immunol, 14

Threshold protective levels of serum IgG to Shigella lipopolysaccharide: re-analysis of Shigella vaccine trials data.

Cohen D. et al, (2022), Clin Microbiol Infect

Impact and Control of Sugar Size in Glycoconjugate Vaccines.

Stefanetti G. et al, (2022), Molecules, 27

Frontiers in Shigella Vaccine Development.

MacLennan CA. and Steele AD., (2022), Vaccines (Basel), 10

The Shigella Vaccines Pipeline.

MacLennan CA. et al, (2022), Vaccines (Basel), 10

Include forthcoming?